The city of Tomball, Texas, currently has 7 active clinical trials seeking participants for Arthritis research studies.
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: DM Clinical Research, Tomball, Texas
Conditions: Arthritis, Psoriatic
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: DM Clinical Research, Tomball, Texas
Conditions: Arthritis, Psoriatic
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: DM Clinical Research - Tomball /ID# 254001, Tomball, Texas +1 locations
Conditions: Rheumatoid Arthritis
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Recruiting
An open label phase 3 study
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Sunpharma site no. 01, Tomball, Texas
Conditions: Psoriatic Arthritis
A Study of Baricitinib in Participants With Rheumatoid Arthritis
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: Dynamed Clinical Research, LP d/b/a DM Clinical Research, Tomball, Texas
Conditions: Rheumatoid Arthritis
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Recruiting
This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Sunpharma site no. 01, Tomball, Texas
Conditions: Active Psoriatic Arthritis
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)
Recruiting
RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/11/2023
Locations: Anaptys Bio Investigative Site 10-121, Tomball, Texas
Conditions: Rheumatoid Arthritis